Mirxes Holding Company Limited

02629.HK

Develops blood-based miRNA in vitro diagnostic products for disease screening in Asia, headquartered in Singapore. Its core product, GASTROClear, is a 12-biomarker blood test for gastric cancer screening, commercialized in Singapore with HSA Class C IVD certification.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Single product, business line or region
• Overseas markets and operations
• Business changes and acquisitions
• Capacity and utilisation
• Seasonality and cyclicality
• Losses and path to profitability
• Decline in revenue or profit
• Net current liabilities or net liabilities
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Indebtedness, guarantees and other contingent obligations
• Non-recurring gains and losses
• Chapter 18A biotech